Literature DB >> 8725271

Cathepsin A deficiency in galactosialidosis: studies of patients and carriers in 16 families.

W J Kleijer1, G C Geilen, H C Janse, O P van Diggelen, X Y Zhou, N J Galjart, H Galjaard, A d'Azzo.   

Abstract

Deficiency of lysosomal protective protein/cathepsin A in humans is the primary cause of galactosialidosis, a lysosomal storage disease characterized by combined deficiency of beta-galactosidase and neuraminidase. We have investigated 20 galactosialidosis patients and nine of their obligate heterozygous parents. A group of 12 patients with the early infantile type of the disease exhibited practically complete absence of cathepsin A activity, whereas eight patients with either the late infantile or the juvenile/adult type had 2-5% residual activity. Highest levels (5%) were present in two patients with milder clinical manifestations and later onset of the disease. In most fibroblast strains, beta-galactosidase activity was 10-15% of normal levels, whereas neuraminidase was reduced to less than 4%. Interestingly, a substantial residual activity (10%) of the latter enzyme was detected in the patient with the mildest phenotype and the highest cathepsin A activity. Heterozygous values for cathepsin A were reduced on average to half of normal levels. However, in two cell strains, the activity was far below control range, and in these cases, neuraminidase activity was severely depressed. Finally, we showed that cathepsin A had considerable activity in chorionic villi and amniocytes, but was deficient in amniocytes from a pregnancy with an affected fetus, indicating the relevance of cathepsin A assay for prenatal diagnosis of galactosialidosis.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8725271     DOI: 10.1203/00006450-199606000-00022

Source DB:  PubMed          Journal:  Pediatr Res        ISSN: 0031-3998            Impact factor:   3.756


  7 in total

1.  LPS-induced cytokine production in human dendritic cells is regulated by sialidase activity.

Authors:  Nicholas M Stamatos; Ivan Carubelli; Diantha van de Vlekkert; Erik J Bonten; Nadia Papini; Chiguang Feng; Bruno Venerando; Alessandra d'Azzo; Alan S Cross; Lai-Xi Wang; Peter J Gomatos
Journal:  J Leukoc Biol       Date:  2010-09-08       Impact factor: 4.962

2.  Clinical utility of whole-exome sequencing in rare diseases: Galactosialidosis.

Authors:  Carlos E Prada; Claudia Gonzaga-Jauregui; Rebecca Tannenbaum; Samantha Penney; James R Lupski; Robert J Hopkin; V Reid Sutton
Journal:  Eur J Med Genet       Date:  2014-04-24       Impact factor: 2.708

3.  The atomic model of the human protective protein/cathepsin A suggests a structural basis for galactosialidosis.

Authors:  G Rudenko; E Bonten; W G Hol; A d'Azzo
Journal:  Proc Natl Acad Sci U S A       Date:  1998-01-20       Impact factor: 11.205

Review 4.  Clinical aspects of neuropathic lysosomal storage disorders.

Authors:  Laura Bannach Jardim; Maria Mercedes Villanueva; Carolina F Moura de Souza; Cristina B Oliveira Netto
Journal:  J Inherit Metab Dis       Date:  2010-05-21       Impact factor: 4.982

5.  Transport of human lysosomal neuraminidase to mature lysosomes requires protective protein/cathepsin A.

Authors:  A van der Spoel; E Bonten; A d'Azzo
Journal:  EMBO J       Date:  1998-03-16       Impact factor: 11.598

6.  Identification of embryonic lethal genes in humans by autozygosity mapping and exome sequencing in consanguineous families.

Authors:  Hanan E Shamseldin; Maha Tulbah; Wesam Kurdi; Maha Nemer; Nada Alsahan; Elham Al Mardawi; Ola Khalifa; Amal Hashem; Ahmed Kurdi; Zainab Babay; Dalal K Bubshait; Niema Ibrahim; Firdous Abdulwahab; Zuhair Rahbeeni; Mais Hashem; Fowzan S Alkuraya
Journal:  Genome Biol       Date:  2015-06-03       Impact factor: 13.583

7.  The uterine expression of SEC63 gene is up-regulated at implantation sites in association with the decidualization during the early pregnancy in mice.

Authors:  Ren-wei Su; Zhao-gui Sun; Yue-chao Zhao; Qiu-ju Chen; Zeng-ming Yang; Run-sheng Li; Jian Wang
Journal:  Reprod Biol Endocrinol       Date:  2009-02-11       Impact factor: 5.211

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.